Izabela Oleksak

Izabela Oleksak

Auto-generated profile, based on publicly available information

Izabela Oleksak

Student Scientific Society, Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
IWIwona Welian-Polus
Iwona Welian-Polus
MLMichał Leśniewski
Michał Leśniewski
KMKarolina Maliszewska
Karolina Maliszewska
IOIzabela Oleksak
Izabela Oleksak
JZJoanna Ziółkowska
Joanna Ziółkowska
WWWiktoria Wilanowska
Wiktoria Wilanowska
Introduction and purpose: A collection of symptoms known as cerebral palsy first manifest in early childhood and result in profound physical impairment. Cerebral palsy is thought to affect 1 in 500 live births, or roughly 17 million people worldwide. The type of cerebral palsy determines the clinical symptoms. Movement coordination disorders, epilepsy, muscle weakness, and feeding difficulties are the most common symptoms. The purpose of this article is to familiarize readers with the options for nutritional therapy for cerebral palsy patients. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included cerebral palsy; nutrition; treatment; gut microbiota.. State of knowledge Early identification of malnutrition symptoms and appropriate interventions, such as the implantation of a percutaneous endoscopic gastrostomy tube in patients who are unable to swallow food, are the cornerstones of nutritional therapy for cerebral palsy patients. Dysphagia is a major problem in the population of patients with cerebral palsy, and multidisciplinary therapy is necessary for them. Patients' serum vitamin D levels are also influenced by their diet; 50% of those with cerebral palsy have a deficiency in this nutrient. Conclusions For people with cerebral palsy, nutrition is very important. Premature death may arise from malnutrition brought on by the disease's advancement. As a result, individuals with cerebral palsy need to receive specialized care

12 May 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
WWWiktoria Wilanowska
Wiktoria Wilanowska
AGAnna Greguła
Anna Greguła
KSKarol Stachyrak
Karol Stachyrak
DMDawid Mika
Dawid Mika
JMJustyna Matuszewska
Justyna Matuszewska
KTKamila Turek
Kamila Turek
Introduction and purposeCariprazine is an atypical antipsychotic drug approved for the treatment of schizophrenia, as well as manic and mixed episodes associated with bipolar disorder. It functions as a dopamine multifunctional agent, a partial agonist at dopamine and serotonin receptors. Unlike the majority of antipsychotics, which primarily target positive symptoms through dopaminergic antagonism, often neglecting negative, cognitive, and affective symptoms, the unique cariprazine's pharmacological profile, particularly potent blockade of D3 dopamine receptors, suggests the potential for numerous clinical applications. The aim of this study is to present current knowledge of cariprazine, focusing particularly on its mechanism of action, potential applications, adverse effects, and pharmacokinetic properties that could impact its clinical use.Methods and materialsA review of the literature available in the PubMed database was performed using the key words: cariprazine; atypical antipsychotic drug; antipsychotic medication; schizophrenia treatment; bipolar disorder treatment; mania treatment; depression treatment, dopamine agonist.ConclusionsCariprazine demonstrates a unique pharmacological profile, offering potential benefits in managing a wide range of psychiatric disorders, including schizophrenia, bipolar disorder (mania, depression, mixed episodes), unipolar depression, and co-occurring substance use disorders. Clinical studies have shown efficacy in reducing symptoms and improving negative and cognitive function, with a favorable metabolic profile, minimal impact on cardiovascular system, and generally mild adverse effect profile. However, further research is necessary to explore its full therapeutic potential and optimize its clinical use in diverse patient populations.

15 May 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
JMJustyna Matuszewska
Justyna Matuszewska
KBKamila Babkiewicz-Jahn
Kamila Babkiewicz-Jahn
ASAdrianna Szymańska
Adrianna Szymańska
WWWiktoria Wilanowska
Wiktoria Wilanowska
IOIzabela Oleksak
Izabela Oleksak
NZNatalia Załęska
Natalia Załęska
Introduction and purpose Munchausen syndrome by proxy is a factitious disorder characterized by the search for and induction of somatic symptoms, the falsification of laboratory results, and even the mutilation of a loved one, usually a child, by a parent or caregiver. Paediatricians often only have information about the child's condition from an interview with the child’s guardian, so it is very important to differentiate feigned disorders from real, sometimes difficult to diagnose, cases of illness. We may suspect them if the parent reports unusual symptoms in the child, insinuates further treatments and hospital stays, has above-average knowledge of medical terminology, and is aggressive towards the staff. Prominent among the causes of Munchausen syndrome by proxy are first and foremost the desire to focus the parent/carer’s attention on themselves and the expectation of recognition for their care and concern for the child. Methods and materials The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included munchausen syndrome, munchausen syndrome by proxy, treatment, diagnosis, paediatric condition falsification, factitious disorder. Conclusions Due to the nature of this disorder, physicians of different specialities may come across it during their practice. Increasing their knowledge on this topic and the effects of Munchausen syndrome by proxy will allow the correct diagnosis to be established and appropriate psychiatric therapy with psychological care to be introduced, as well as protecting children who are victims of the actions of their caregivers.

7 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
IOIzabela Oleksak
Izabela Oleksak
MLMichał Leśniewski
Michał Leśniewski
IWIwona Welian-Polus
Iwona Welian-Polus
KMKarolina Maliszewska
Karolina Maliszewska
JZJoanna Ziółkowska
Joanna Ziółkowska
Introduction and purpose: Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent. It has been observed recently that alterations in the gut microbiota are associated with the onset of neurodegenerative disorders. This research aims to estimate the pathomechanisms and disease courses associated with the gut microbiota that lead to AD and PD development. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included Alzheimer’s disease; Parkinson’s disease; gut microbiota; neurodegenerative diseases. State of knowledge The advancement of neurodegenerative processes is linked to the varying progressive course of both disorders. There are numerous likely reasons that connect the development of AD and PD and the gut microbiome. These include the hypotheses on inflammation, the decrease in the quantity of bacteria that produce short-chain fatty acids, and hygiene. The researchers' suggested treatment plans for the two illnesses are comparable. Conclusions A major influence on the development of neurodegenerative disorders is the gut microbiome. To clarify the precise connections between the gut microbiota and the development of AD and PD, further thorough research is required. More human research is required. Furthermore, it's possible that early interventions, such switching to a Mediterranean diet, are anticipated to lower the risk of AD or PD.

15 May 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KBKamila Babkiewicz-Jahn
Kamila Babkiewicz-Jahn
JMJustyna Matuszewska
Justyna Matuszewska
ASAdrianna Szymańska
Adrianna Szymańska
WWWiktoria Wilanowska
Wiktoria Wilanowska
IOIzabela Oleksak
Izabela Oleksak
NZNatalia Załęska
Natalia Załęska
Introduction and purpose Heart failure has become a civilization disease, affecting 1-2% of the world's population. It is a condition with various etiologies and phenotypes. The annual mortality rate due to heart failure is approximately 10%, with organ dysfunction caused by hypoperfusion and sudden cardiac death being the leading causes of death. The aim of this study is to present current knowledge of heart failure, focusing on its pathophysiology, and the mechanism of action and applications of sacubitril/valsartan. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included pathophysiology of heart failure; natriuretic peptide pathways; treatment of heart failure; sacubitril/valsartan. Conclusions Heart failure is a syndrome marked by the activation of various neurohormonal systems such as the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS) and natriuretic peptides (NP). Historically, the therapeutic approach has focused on reducing RAAS activity and SNS activity. In recent years, increasing attention has been given to potential benefits associated with the NP system. Following disappointing outcomes from studies involving neprilysin (NEP) inhibitors, administered alone or in conjunction with an ACE inhibitor and vasopeptidase inhibitors, there have been findings with the pharmacological class termed ARNI (angiotensin receptor and NEP inhibitors). Sacubitril/valsartan has proven to be an effective and safe treatment that reduces the need for hospitalization, enhances the quality of life and longevity of patients with chronic HFrEF.

24 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MLMichał Leśniewski
Michał Leśniewski
IWIwona Welian-Polus
Iwona Welian-Polus
IOIzabela Oleksak
Izabela Oleksak
KMKarolina Maliszewska
Karolina Maliszewska
Neurofibromatosis is one of the most common genetic diseases. It is inherited in an autosomal dominant manner. It is divided into two genetically distinct subtypes, characterised by multiple skin lesions and tumours of the peripheral and central nervous system. Neurofibromatosis type 1, or Recklinghausen's disease, is the most common phakomatosis. The disease is genetically determined by a mutation of the neurofibromin- 1 gene on chromosome 17. Neurofibromatosis type 2 accounts for 3% of all cases. The disease is genetically determined - caused by a mutation of the neurofibromin-2 gene on chromosome 22. The diagnostic and therapeutic process of neurofibromatosis is a major challenge for clinicians. Given the complexity of the problem, we have reviewed the literature on the diagnostic and therapeutic possibilities of the disease.